Indian pharma firms launch cheaper generic semaglutide for diabetes, obesity
text_fields
Three major Indian drugmakers have introduced low-cost generic versions of Semaglutide injections following the expiry of its patent, expanding access for patients with Type 2 Diabetes and obesity.
Sun Pharma, Zydus Lifesciences, and Dr. Reddy's Laboratories launched their products a day after Natco Pharma introduced its version priced at about Rs 1,290 per month.
Sun Pharma unveiled two brands, Noveltreat for chronic weight management and Sematrinity for diabetes, with weekly therapy costs ranging from around Rs 750 to Rs 2,000 depending on dosage.
Zydus Lifesciences introduced its product under brand names SEMAGLYN, MASHEMA, and ALTERME in a reusable multi-dose pen, with an estimated monthly cost of about Rs 2,200.
Dr. Reddy’s Laboratories launched Obeda, described as India’s first drug regulator-approved generic semaglutide for Type 2 diabetes, priced at about Rs 4,200 per month for once weekly use in pre-filled pens.
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, widely used to improve blood sugar control and support weight loss.
The launches are expected to significantly reduce treatment costs and improve accessibility in India, where demand for diabetes and obesity therapies is rising.
According to the Ministry of Commerce and Industry, India’s pharmaceutical exports grew by 9.4 percent in 2024–25 to $30.47 billion, with the sector projected to expand from about $60 billion currently to $130 billion by 2030.
India ranks third globally in terms of medicine production volume and exports pharmaceutical products to more than 200 countries.
